NICE recommends J&J's Invokana; OTC Viagra cream looks promising; Pfizer's Elelyso gets kosher tag;

@FiercePharma: Top-read on FP Thurs: CDC backing for preventive Truvada could multiply Gilead's scripts 50-fold. Story | Follow @FiercePharma

@TracyStaton: ICYMI this week: Prepping for $25B merger, Actavis taps Forest CEO Saunders to lead combined company. Report | Follow @TracyStaton

@EricPFierce: Takashi Shoda, who was CEO at Daiichi Sankyo when it bought Ranbaxy for $4.6B, steps down as chairman. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: ICYMI earlier: Thursday's edition of FierceVaccines. Report | Follow @CarlyHFierce

> The U.K. price and effectiveness arbiter NICE has recommended use of Johnson & Johnson's ($JNJ) Invokana for type 2 diabetes. Story

> The FDA had U.S. Marshals seize $11.2 million worth of drugs marketed by Ascend Laboratories of Montvale, NJ, and distributed by Masters Pharmaceuticals, of Cincinnati, OH. because they ear drops and other products had not been approved by the FDA. Release

> Fresenius says its generics sterile injectable drug unit Kabi should be able to grow this year in Asia. 

> A massive dose of a measles vaccine was found to wipe out a blood cancer that had spread inside the body of a patient involved in a clinical trial. Report

> Cambridge, MA biotech Strategic Science and Technologies says a Phase 1 trial of a reformulation of Pfizer's ($PFE) Viagra as a cream that could be sold over-the-counter, showed it to have fewer side effects than the pill. Story

Medical Device News

@FierceMedDev: Inspire Medical snares $40M to launch sleep apnea device. Story | Follow @FierceMedDev

@VarunSaxena2: Alnylam's hepatitis B therapy shows promise in animal studies. More | Follow @VarunSaxena2

@MichaelGFierce: Boston College team makes zinc nano-cages for 'smart' cancer drug delivery. Story | Follow @MichaelGFierce

@EmilyWFierce: Stabilizing spoon counteracts tremors, helps Parkinson's patients eat. News | Follow @EmilyWFierce

> FDA creates two new 510(k) clearance categories. Item

> Boston Scientific buyout threatens Cardiovascular Systems. More

> Keystone Heart nets $14M for TAVR cerebral protection device. Article

Biotech News

@FierceBiotech: EuroBiotech: J&J and Pfizer pursue contrasting strategies, AZ backs biotech fund, Bayer opens Berlin incubator. Report | Follow @FierceBiotech

@JohnCFierce: Good company, Gates Foundation and Wellcome Trust put $40M in Kymab's Kymouse, Gates to partner on vaccines work. Release | Follow @JohnCFierce

@DamianFierce: Three biotech VC rounds total ~$100M for startups. More | Follow @DamianFierce

@EmilyMFierce: ICYMI from FierceVaccines: Computer model can boost child vaccination rates while cutting costs. Article | Follow @EmilyMFierce

> Kamada tanks as its lead drug can't top placebo. More

> Proteon banks $45M for vascular drug with Novartis in the rearview. Article

> FDA rejects Novartis' 'breakthrough' cardio drug serelaxin. News

And Finally... The Orthodox Union has granted its first-ever kosher certification to Pfizer's Elelyso (taliglucerase alfa) for the long-term treatment of adults with Type 1 Gaucher disease, a genetic condition common among Jews. Release

Suggested Articles

With a brand new approval for Adakveo under its belt, Novartis Sunday flaunted an analysis showing the drug could cut patient hospitalizations by 40%.

BeiGene only just won its first Brukinsa nod in MCL. But it’s already pushing to join the CLL field, and Sunday it rolled out more data.

How long can one infusion of CAR-T drug Yescarta continue helping patients with refractory large B-cell lymphoma? Pretty long, Gilead showed Saturday.